Literature DB >> 19203854

Molecular basis of severe myoclonic epilepsy in infancy.

Kazuhiro Yamakawa1.   

Abstract

Severe myoclonic epilepsy (SMEI) or Dravet syndrome is caused by mutations of the SCN1A gene that encodes voltage-gated sodium channel alpha-1 subunit. Recently, we generated and characterized a knock-in (KI) mice with an SCN1A nonsense mutation that appeared in three independent SMEI patients. The SCN1A-KI mice well reproduced the SMEI disease phenotypes. Both homozygous and heterozygous knock-in mice developed epileptic seizures within the first postnatal month. In heterozygous knock-in mice, trains of evoked action potentials in inhibitory neurons exhibited pronounced spike amplitude decrement late in the burst but not in pyramidal neurons. We further showed that in wild-type mice the Nav1.1 protein is expressed dominantly in axons and moderately in somata of parbalbumin (PV) - positive inhibitory interneurons. Our immunohistochemical observations of the Nav1.1 are clearly distinct to the previous studies, and our findings has corrected the view of the Nav1.1 protein distribution. The data indicate that Nav1.1 plays critical roles in the spike output from PV interneurons and further, that the specifically altered function of these inhibitory circuits may contribute to epileptic seizures in the mice. These information should contribute to the understanding of molecular pathomechanism of SMEI and to develop its effective therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19203854     DOI: 10.1016/j.braindev.2008.11.015

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  5 in total

Review 1.  Genetic and biologic classification of infantile spasms.

Authors:  Alex R Paciorkowski; Liu Lin Thio; William B Dobyns
Journal:  Pediatr Neurol       Date:  2011-12       Impact factor: 3.372

2.  Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.

Authors:  Lyndsey L Anderson; Marika Heblinski; Nathan L Absalom; Nicole A Hawkins; Michael T Bowen; Melissa J Benson; Fan Zhang; Dilara Bahceci; Peter T Doohan; Mary Chebib; Iain S McGregor; Jennifer A Kearney; Jonathon C Arnold
Journal:  Br J Pharmacol       Date:  2021-09-30       Impact factor: 9.473

3.  Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome.

Authors:  Lyndsey L Anderson; Michael Udoh; Declan Everett-Morgan; Marika Heblinski; Iain S McGregor; Samuel D Banister; Jonathon C Arnold
Journal:  J Cannabis Res       Date:  2022-01-04

4.  GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer's Disease Models.

Authors:  Jesse E Hanson; Keran Ma; Justin Elstrott; Martin Weber; Sandrine Saillet; Abdullah S Khan; Jeffrey Simms; Benjamin Liu; Thomas A Kim; Gui-Qiu Yu; Yelin Chen; Tzu-Ming Wang; Zhiyu Jiang; Bianca M Liederer; Gauri Deshmukh; Hilda Solanoy; Connie Chan; Benjamin D Sellers; Matthew Volgraf; Jacob B Schwarz; David H Hackos; Robby M Weimer; Morgan Sheng; T Michael Gill; Kimberly Scearce-Levie; Jorge J Palop
Journal:  Cell Rep       Date:  2020-01-14       Impact factor: 9.423

5.  Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.

Authors:  Lyndsey L Anderson; Nathan L Absalom; Sarah V Abelev; Ivan K Low; Peter T Doohan; Lewis J Martin; Mary Chebib; Iain S McGregor; Jonathon C Arnold
Journal:  Epilepsia       Date:  2019-10-17       Impact factor: 5.864

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.